Why is Pfizer falling/rising?

As of 25-Jul, Pfizer Ltd. is experiencing a price increase, currently at 5,340.50, reflecting a rise of 85.5 points or 1.63%. Today's price summary indicates that the stock outperformed its sector by 1.46%, reaching an intraday high of Rs 5434.95, which is a 3.42% increase. The stock is trading above its 5-day, 100-day, and 200-day moving averages, although it is below its 20-day and 50-day moving averages. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 21.29% compared to the 5-day average. Despite some concerns regarding long-term growth, the company showcases strong management efficiency with a high return on equity (ROE) of 19.67% and a low debt-to-equity ratio, which may contribute positively to investor sentiment.
In the broader market context, Pfizer's short-term performance over the past week shows a gain of 0.39%, contrasting with a decline of 0.36% in the Sensex, indicating that Pfizer is performing better than the benchmark in the short term. However, over the past month, Pfizer's stock has decreased by 3.39%, while the Sensex has fallen by a lesser 1.56%. This suggests that while Pfizer is currently experiencing a rise, its longer-term performance has been less favorable compared to the broader market, with a year-to-date return of 1.64% against the Sensex's 4.25%. The stock's high dividend yield of 3.81% may also attract investors, despite its expensive valuation relative to peers, as indicated by the high price-to-book value ratio.